Literature DB >> 4000279

Synthesis and structure of the platelet aggregation factor thromboxane A2.

S S Bhagwat, P R Hamann, W C Still, S Bunting, F A Fitzpatrick.   

Abstract

In 1975, Hamberg et al. reported evidence for the existence of an unstable platelet-aggregating factor which they named thromboxane A2 (TXA2) and for which they proposed a novel bicyclic oxetane structure (1, below) based on the short half-life of the factor (t1/2 (37 degrees C) = 32 s at pH 7.4) and the isolation of degradation products related to thromboxane (TXB2) (2, below). As natural TXA2 has not yet been isolated and characterized as a pure compound, we have synthesized the proposed structure (1) from TXB2 and compared its biological properties with those of authentic, biologically generated material. Here we present evidence that synthetic material having structure (1) is indistinguishable from platelet-derived TXA2 in various biological assays and that the proposed structure (1) for TXA2 is correct.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4000279     DOI: 10.1038/315511a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  18 in total

1.  Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.

Authors:  W N Charman; S A Charman; D C Monkhouse; S E Frisbee; E A Lockhart; S Weisman; G A Fitzgerald
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

Review 2.  The role of nitric oxide in prostaglandin biology; update.

Authors:  Sangwon F Kim
Journal:  Nitric Oxide       Date:  2011-07-26       Impact factor: 4.427

Review 3.  Platelet "first responders" in wound response, cancer, and metastasis.

Authors:  David G Menter; Scott Kopetz; Ernest Hawk; Anil K Sood; Jonathan M Loree; Paolo Gresele; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

Review 4.  Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Authors:  H Patscheke
Journal:  Blut       Date:  1990-05

Review 5.  Employing chemical synthesis to study the structure and function of colibactin, a "dark matter" metabolite.

Authors:  Peyton C Williams; Kevin M Wernke; Alina Tirla; Seth B Herzon
Journal:  Nat Prod Rep       Date:  2020-11-18       Impact factor: 13.423

Review 6.  Endothelial cell function in diabetic microangiopathy.

Authors:  M Porta; M La Selva; P Molinatti; G M Molinatti
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

Review 7.  Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family?

Authors:  Harold J Ting; Fadi T Khasawneh
Journal:  J Biomed Sci       Date:  2010-04-06       Impact factor: 8.410

8.  Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk.

Authors:  M T Olson; T S Kickler; J A Lawson; R C McLean; J Jani; G A FitzGerald; J J Rade
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

9.  Inhibition of pulmonary thromboxane A2 synthase activity and airway responses by CGS 13080.

Authors:  D B McNamara; J K Harrington; J A Bellan; G B Graybar; D C Underwood; P J Kadowitz
Journal:  Mol Cell Biochem       Date:  1989-01-23       Impact factor: 3.396

10.  Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.

Authors:  S Narumiya; M Okuma; F Ushikubi
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.